What's new? Log in Free sign up

Abbvie (ABBV) Environmental, Social & Governance (ESG) Data

Company Profile

Search within these filings

View filings

Exhibits within filings

Filing insights

Export filings list

Export a CSV file of filings or unique filing companies (up to first 5,000 results).

Download list of filings Download list of companies

Employees

Data from SEC filings

Employee count

CEO pay ratio

CEO Salary

Median Employee Salary

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

Definitive proxy

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

Definitive proxy

UN Sustainable Development Goals (SDGs)

Definitive proxy

ESG term mentions

In last year of SEC filings

Air Biodegradable Carbon Carbon Emissions Carbon Footprint Climate Climate Change Emission Environment Environmental Environmental Protection Forest Fossil Fuel Greenhouse Gas Emission Life Cycle Materials Nature Offset Packaging Pandemic Petroleum Planet Plastic Pollution Raw Materials Regenerative Resiliency Science Based Targets Scope 1 Superfund Access Affordability Asian Benefits Black Charitable Charity Citizenship Community Culture Customer Cyber Cybersecurity Data Privacy Death Demographic Disability Diversity Diversity and Inclusion Drug Pricing EEO-1 Employee Employee Engagement Employee Resource Group Engagement Ethnicity Gender Health and Safety Health Care Healthcare Hire Hiring Human Capital Human Resources Human Rights Incident Inequality Injured Injury LGBTQ Opioid Paid Leave Parental Leave Pay Equity Pay for Performance Perquisites Philanthropy Privacy Product Quality Recall Recruitment Reimbursement Retention Retirement Safety Satisfaction Skill Skilled Skills Social Social License to Operate Societal Society Stakeholder Supplier Supply Chain Talent Training Union Volunteer Women Workforce Action Plan Anti-corruption Antitrust Assessment Assurance Attorney General Audit Board Oversight Bonus Bribery Chronic Class Action Lawsuit Classified Claw Back Clawback Commitment Committee Evaluation Conflict of Interest Controversy Corporate Governance Corporate Purpose Corporate Social Responsibility Corruption Department of Downward Discretion Enterprise Risk Management ERM ESG Ethics Executive Compensation Expert Fined Fraud Goals Governance Hedging Incentive Incentivize Independence Independent Independent Chair Inequality Innovate Innovation Innovative Investigation KPI Lawsuit Lead Independent Director Leadership Litigation Long-term Majority Mission Overboarding Oversee Oversight Perquisite Plaintiff Pledging Poison Pill Political Expenditures Political Spending Procurement Proxy Access Purpose Quality Standard R&D Recoup Reputation Reputational Reputational Risk Research and Development Responsibility Responsible Self-evaluation Shareholder Proposals Single Trigger Special Meeting Stockholder Engagement Strategy Supermajority Sustainability Sustainable Targets Tax Tenure Transparency Voting Rights

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

ABBV Abbvie Inc

Letter to shareholders

ABBV Abbvie Inc

Letter to shareholders

ABBV Abbvie Inc

Letter to shareholders

ABBV Abbvie Inc

Letter to shareholders

ABBV Abbvie Inc

Letter to shareholders

ABBV Abbvie Inc

Letter to shareholders

ABBV Abbvie Inc

Letter to shareholders

ABBV Abbvie Inc

Letter to shareholders

ABBV Abbvie Inc

Letter to shareholders

ABBV Abbvie Inc

Letter to shareholders

ABBV Abbvie Inc

Letter to shareholders

Vote support at last AGM

AbbVie Inc. (“AbbVie”) held its Annual Meeting of Stockholders on May 6, 2022. The following is a summary of the matters voted on at that meeting.

(1)	The stockholders elected AbbVie’s Class I Directors with terms expiring in 2025, as follows:

Name		For		Against		Broker Non-Votes
William H. L. Burnside		1,192,356,325		39,395,112		259,540,346
Thomas C. Freyman		1,197,976,130		33,775,307		259,540,346
Brett J. Hart		1,192,330,735		39,420,702		259,540,346
Edward J. Rapp		1,133,656,046		98,095,391		259,540,346

(2)	The stockholders ratified the appointment of Ernst & Young LLP as AbbVie’s independent registered public accounting firm for 2022, as follows:

For		Against		Abstain
1,478,250,755		9,770,581		3,270,447

(3)	The stockholders approved, on an advisory basis, the compensation of AbbVie’s named executive officers listed in the proxy statement for the 2022 annual meeting, as follows:

For		Against		Abstain		Broker Non-Votes
1,096,289,157		128,833,558		6,628,722		259,540,346

(4)	The stockholders did not approve the management proposal regarding amendment of the certificate of incorporation to eliminate supermajority voting, as follows:

For		Against		Abstain		Broker Non-Votes
1,218,279,066		8,897,735		4,574,636		259,540,346

(5)	The stockholders did not approve a stockholder proposal to adopt a policy to require an independent chair, as follows:

For		Against		Abstain		Broker Non-Votes
371,759,169		854,161,715		5,830,553		259,540,346

(6)	The stockholders approved a stockholder proposal to seek shareholder approval of certain termination pay arrangements, as follows:

For		Against		Abstain		Broker Non-Votes
617,084,685		608,049,472		6,617,280		259,540,346

(7)	The stockholders did not approve a stockholder proposal to issue a report on board oversight of competition practices, as follows:

For		Against		Abstain		Broker Non-Votes
404,279,676		810,098,505		17,373,256		259,540,346

(8)	The stockholders did not approve a stockholder proposal to issue an annual report on political spending, as follows:

For		Against		Abstain		Broker Non-Votes
484,276,406		740,658,343		6,816,668		259,540,346

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.